查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726238

Aminoglycosides市场规模、份额、趋势分析报告：按产品、给药途径、应用、地区、细分市场预测，2025-2030 年

Aminoglycosides Market Size, Share & Trends Analysis Report By Product, By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

Aminoglycosides市场的成长与趋势

根据 Grand View Research, Inc. 的新报告，预计到 2030 年全球Aminoglycosides市场规模将达到 24.5 亿美元。

预计 2025 年至 2030 年间，市场复合年增长率将达到 4.34%。随着动物疾病发病率的增加，导致抗生素的广泛使用，预计需求将增加。

然而，由于严重的耳毒性、肾毒性和神经肌肉阻断等副作用，Aminoglycosides抗生素的普及率预计会下降，对市场成长产生不利影响。此外，监管机构不赞成使用某些Aminoglycosides抗生素也预计会减缓该行业的成长。

Aminoglycosides市场报告重点

  • 预计预测期内妥布霉素市场将显着成长。妥布霉素是一种强效Aminoglycosides抗生素，由于其对革兰氏阴性细菌，尤其是铜绿假单胞菌具有频谱功效，在全球Aminoglycosides抗生素行业中占有重要地位。
  • 根据给药途径，市场细分为注射剂、饲料、乳房内、局部、口服和注射剂，其中註射剂在 2024 年的市场占有率为 26.73%。
  • 预计在预测期内，皮肤感染疾病将以最快的复合年增长率成长。皮肤感染疾病是市场的主要驱动力，因为其盛行率高，而且Aminoglycosides在治疗革兰氏阴性病菌感染有效。
  • 2024 年，北美Aminoglycosides製药业将占全球销售额的 37.60%。这一巨大份额是由于北美普遍存在的细菌感染以及影响数百万人的成熟医疗保健基础设施。

目录

第一章调查方法与范围

第二章执行摘要

第三章Aminoglycosides市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • Aminoglycosides市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
    • 定价分析
    • 管道分析

第四章Aminoglycosides市场：产品、估计与趋势分析

  • 全球Aminoglycosides市场：产品仪表板
  • 全球Aminoglycosides药物市场：产品差异分析
  • 全球Aminoglycosides市场（按产品和收益）
  • 新霉素
  • 妥布霉素
  • 庆大霉素
  • Amikacin
  • Paromomycin
  • 链霉素
  • 卡那霉素
  • 其他的

第五章Aminoglycosides市场：依给药途径、估计及趋势分析

  • 全球Aminoglycosides市场：给药途径仪表板
  • 全球Aminoglycosides市场：给药途径变异分析
  • 全球Aminoglycosides市场（依给药途径及收益）
  • 注射
  • 餵食
  • 在乳房中
  • 局部的
  • 口服

第六章Aminoglycosides市场：应用、预测与趋势分析

  • 全球Aminoglycosides市场：应用仪表板
  • 全球Aminoglycosides市场：应用趋势分析
  • 全球Aminoglycosides市场（按应用和收益）
  • 皮肤感染疾病
  • 尿道感染及骨盆腔疾病
  • 兽医
  • 呼吸系统疾病
  • 其他的

第七章Aminoglycosides市场：按治疗、治疗层级和地区分類的估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 2024年主要企业市场占有率分析
    • Pfizer Inc.
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd
    • Cipla
    • Sun Pharmaceutical Industries Ltd.
    • Lupin
    • Aurobindo Pharma Limited
    • Fresenius Kabi
    • Viatris Inc.
Product Code: 978-1-68038-630-1

Aminoglycoside Market Growth & Trends:

The global aminoglycosides market size is anticipated to reach USD 2.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.34% from 2025 to 2030. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics.

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.

Aminoglycoside Market Report Highlights:

  • Tobramycin is expected to exhibit significant growth in the market over the forecast period. It is a potent aminoglycoside antibiotic that plays a critical role in the global aminoglycosides industry due to its broad-spectrum efficacy against Gram-negative bacteria, particularly Pseudomonas aeruginosa.
  • Based on route of administration, the market is categorized into injectable, feed, intra-mammary, topical, oral, and injectable, led the market with a market share of 26.73% in 2024.
  • Skin infections are anticipated to grow at the fastest CAGR over the forecast period. Skin infections represent a significant driver for the market, owing to their high prevalence and the effectiveness of aminoglycosides in treating gram-negative bacterial infections.
  • The North America aminoglycosides industry held 37.60% of the global revenue share in 2024. This large share is attributed to bacterial infections, which are dominant in North America, and a well-established healthcare infrastructure affecting millions of people.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and route of administration outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Aminoglycosides Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of bacterial infections
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Aminoglycosides Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Aminoglycosides Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Aminoglycosides Market: Product Dashboard
  • 4.2. Global Aminoglycosides Market: Product Movement Analysis
  • 4.3. Global Aminoglycosides Market by Product, Revenue
  • 4.4. Neomycin
    • 4.4.1. Neomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Tobramycin
    • 4.5.1. Tobramycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Gentamicin
    • 4.6.1. Gentamicin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Amikacin
    • 4.7.1. Amikacin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Paromomycin
    • 4.8.1. Paromomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Streptomycin
    • 4.9.1. Streptomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Kanamycin
    • 4.10.1. Kanamycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Aminoglycosides Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Aminoglycosides Market: Route of Administration Dashboard
  • 5.2. Global Aminoglycosides Market: Route of Administration Movement Analysis
  • 5.3. Global Aminoglycosides Market by Route of Administration, Revenue
  • 5.4. Injectable
    • 5.4.1. Injectable monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Feed
    • 5.5.1. Feed market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Intra-mammary
    • 5.6.1. Intra-mammary market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Topical
    • 5.7.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Oral
    • 5.8.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Aminoglycosides Market: Application Estimates & Trend Analysis

  • 6.1. Global Aminoglycosides Market: Application Dashboard
  • 6.2. Global Aminoglycosides Market: Application Movement Analysis
  • 6.3. Global Aminoglycosides Market by Application, Revenue
  • 6.4. Skin Infection
    • 6.4.1. Skin infection market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. UTI & Pelvic Diseases
    • 6.5.1. UTI & pelvic diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Veterinary
    • 6.6.1. Veterinary market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Respiratory diseases
    • 6.7.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Aminoglycosides Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Pfizer Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Merck & Co. Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. AbbVie Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Teva Pharmaceutical Industries Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Cipla
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Sun Pharmaceutical Industries Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Lupin
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Aurobindo Pharma Limited
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Fresenius Kabi
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Viatris Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 3 North America Aminoglycosides Market, by Route of, 2018 - 2030 (USD Million)
  • Table 4 North America Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 5 U.S. Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 U.S. Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 U.S. Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 8 Canada Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 9 Canada Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Canada Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 Mexico Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Mexico Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 Europe Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 15 Europe Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Europe Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 17 Germany Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 18 Germany Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Germany Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 UK Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 UK Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 UK Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 France Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 24 France Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 France Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Italy Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Italy Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Italy Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 Spain Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 30 Spain Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 Spain Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 China Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 36 China Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 China Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 38 Japan Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 39 Japan Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Japan Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 India Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 India Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 India Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 44 South Korea Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 South Korea Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 South Korea Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Latin America Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Brazil Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Brazil Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 MEA Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 MEA Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 MEA Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 56 South Africa Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 South Africa Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Africa Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 UAE Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 63 UAE Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 UAE Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Aminoglycosides market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and route of administration segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market, (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Aminoglycosides market: Drug outlook and key takeaways
  • Fig. 17 Aminoglycosides market: Drug movement analysis
  • Fig. 18 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Non-ergot Aminoglycosides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Aminoglycosides market: Product outlook and key takeaways
  • Fig. 21 Aminoglycosides market: Product movement analysis
  • Fig. 22 Neomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Tobramycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Gentamicin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Amikacin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Paromomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Streptomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Kanamycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Aminoglycosides market: Route of administration outlook and key takeaways
  • Fig. 31 Aminoglycosides market: Route of administration movement analysis
  • Fig. 32 Injectablesmarket estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Feed market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Intra-mammary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Aminoglycosides market: Application outlook and key takeaways
  • Fig. 38 Aminoglycosides market: Application channel movement analysis
  • Fig. 39 Skin Infection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 UTI & Pelvic Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Veterinary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Aminoglycosides market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America Aminoglycosides market estimates and forecasts, 2018 - 2030 ((USD Million))
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 U.S. Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 Canada Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Target disease prevalence
  • Fig. 57 Europe Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 UK Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 Germany Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 France Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 Spain Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 Italy Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Denmark Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Target disease prevalence
  • Fig. 78 Sweden Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Target disease prevalence
  • Fig. 81 Norway Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Rest of Europe Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Asia Pacific Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 Japan Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 China Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 India Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Target disease prevalence
  • Fig. 95 Australia Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Thailand Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 South Korea Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Rest of Asia Pacific Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Latin America Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Target disease prevalence
  • Fig. 104 Brazil Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 Target disease prevalence
  • Fig. 107 Argentina Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Rest of Latin America Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 MEA Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Target disease prevalence
  • Fig. 112 South Africa Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Target disease prevalence
  • Fig. 115 Saudi Arabia Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Target disease prevalence
  • Fig. 118 UAE Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key country dynamics
  • Fig. 120 Target disease prevalence
  • Fig. 121 Kuwait Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Rest of MEA Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)